Needham & Company LLC Reiterates Buy Rating for G1 Therapeutics (NASDAQ:GTHX)

G1 Therapeutics (NASDAQ:GTHX - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at Needham & Company LLC in a research note issued on Wednesday, Benzinga reports. They presently have a $12.00 target price on the stock. Needham & Company LLC's target price indicates a potential upside of 190.56% from the company's previous close.

Separately, Wedbush reaffirmed an "outperform" rating and set a $5.00 price target (up previously from $4.00) on shares of G1 Therapeutics in a research note on Wednesday, February 28th.

G1 Therapeutics Price Performance

GTHX traded up $0.36 during midday trading on Wednesday, hitting $4.13. The company had a trading volume of 1,007,045 shares, compared to its average volume of 1,261,262. G1 Therapeutics has a twelve month low of $1.08 and a twelve month high of $5.00. The firm's 50-day simple moving average is $3.81 and its 200-day simple moving average is $3.04. The company has a market capitalization of $216.04 million, a PE ratio of -4.24 and a beta of 1.73. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.45 and a current ratio of 3.87.

G1 Therapeutics (NASDAQ:GTHX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.06. G1 Therapeutics had a negative net margin of 58.13% and a negative return on equity of 106.04%. The firm had revenue of $14.87 million during the quarter, compared to analysts' expectations of $12.83 million. During the same quarter in the previous year, the company posted ($0.73) EPS. Equities research analysts predict that G1 Therapeutics will post -0.64 EPS for the current fiscal year.

Insiders Place Their Bets

In other G1 Therapeutics news, insider Rajesh Malik sold 28,600 shares of the company's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $4.62, for a total transaction of $132,132.00. Following the completion of the sale, the insider now owns 169,938 shares in the company, valued at approximately $785,113.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 8.23% of the company's stock.

Hedge Funds Weigh In On G1 Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Creative Financial Designs Inc. ADV raised its position in shares of G1 Therapeutics by 98.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company's stock valued at $108,000 after acquiring an additional 17,475 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its stake in G1 Therapeutics by 68.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 204,200 shares of the company's stock valued at $294,000 after purchasing an additional 82,879 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in G1 Therapeutics in the third quarter worth $189,000. abrdn plc bought a new position in shares of G1 Therapeutics during the fourth quarter worth $1,293,000. Finally, Algert Global LLC acquired a new position in shares of G1 Therapeutics in the 3rd quarter valued at $98,000. Institutional investors own 24.21% of the company's stock.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.